Nancy Chang, Ph.D is Ansun’s CEO and Chairperson of the Board and has served as a Director of Ansun since 2011. Nancy was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors from 2007 to 2012. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine. She has served on the board of a number of companies, including SciClone Pharmaceuticals, Inc., Charles River Laboratories International, Inc., Applied Optoelectronics Inc. Nancy received her Doctorate in Biological Chemistry from Harvard University.
George Y. Wang, Sc.D. has served as Senior Technical Advisor and then Chief Technical Officer at Ansun Biopharma since April 2013. He was the Managing Director of A-Bio Pharma Pte Ltd. in charge of all operations from 2004 until 2008. Prior to that, he was at Tanox, Inc. from 1991 until 2002 and served as Vice President of Process Development and Production. Dr. Wang held various engineering positions at IDEC Pharmaceuticals, BP Amoco Corporation and MGI Pharmaceuticals, Inc. Dr. Wang received his Sc.D. in Biochemical Engineering from Massachusetts Institute of Technology
Dr. Stanley Lewis joined Ansun in 2018 as its Chief Medical Officer. Prior to that, he was the Vice President, Chief Medical Officer of Taimed Biologics where he led the clinical development of Trogarzo® from Phase 1 to BLA licensure in March of 2018. Prior to that he was the Director of Drug Development at Tanox and later a Medical Director at Genentech after which he joined Taimed to lead the Trogarzo® team. He received his M.D. from the University of Texas Medical School and served as a Assistant Professor of Medicine there from 1996-2004. Dr. Lewis is a seasoned CMO with a proven track record.
Mattias Luukkonen joined Ansun as its Chief Legal Officer and Secretary in January 2020. Prior to Ansun, Mattias was Vice President and General Counsel at IntegenX, Inc., where he oversaw all legal operations until the company’s successful acquisition by Thermo Fisher Scientific. Before joining IntegenX, Mattias was a corporate associate at Baker & McKenzie and DLA Piper, where he focused his practice on technology transactions in the life science industry, venture capital financings, M&A and corporate governance. Mattias earned his J.D. summa cum laude from Thomas Jefferson School of Law and a Ph.D. in molecular biology from the Karolinska Institute School of Medicine and the European Molecular Biology Institute.
Dr. Ho joined Ansun in 2017 as its V.P. of Clinical Development. She is also the V.P. of R&D and Clinical Trial Development at Steminent US, Inc., which is a company involved in stem cell therapeutics. She has a long list of accomplishments and awards including: being a Professor at the Graduate Institute of Clinical Medicine, Taipei Medical University; a Director of Medical Research at the Wan Fang Medical Center, Taipei Medical University, Taiwan; being an editorial board member or review on over 10 scientific journals; receiving the Best Clinical Research Award from Taipei Medical University four out of the last seven years; and having 6 patents and publishing over 40 peer reviewed scientific publications. She received her M.D. in 1998 from National Taiwan University and her Ph.D. in Biopharmaceutical Science from the Institute of Biopharmaceutical Science, National Yang-Ming University.
Dr. Lu joined Ansun in 2018 as its V.P. of Quality. Prior to joining Ansun, she had a successful and busy career at Genentech for 10 years, starting as a scientist and advancing to the position of Associate Director of Quality. Dr. Lu has over 20 years of biopharmaceutical and pharmaceutical industry experience in analytical development and quality control for both clinical and marketed products. She also has extensive experience in authoring regulatory filing documents and addressing regulatory agency inquiries/questions.